Open Access
Review
Human Cardiac Organoids: Quantification and Qualification in Cardiovascular Studies
Yingjuan Liu
, Sabu Abraham
, Honglin Xu*
Author Information
Submitted: 4 Apr 2024 | Revised: 29 May 2024 | Accepted: 29 May 2024 | Published: 29 Aug 2024
Abstract
The human cardiac organoids (hCOs) represent a three-dimensional (3D) tissue model that mirrors in vivo cardiac conditions. Recent advancements underscore the immense potential of hCOs in several areas including studying early cardiogenesis, modeling heart diseases, screening potential drugs, and even exploring possibilities for cardiac regeneration. Recognizing the pivotal role hCOs play across various applications, this review examines the evolution of key metrics and tools for assessing cardiac organoids tailored for diverse research objectives. Moreover, it deliberates on the limitations of cardiac organoids and outlines the prospective avenues for future research applications of hCOs.
Keywords
References
1.
Virani, S.S.; Alonso, A.; Aparicio, H.J.; et al. Heart disease and stroke statistics-2021 update: A report from the American heart association. Circulation 2021, 143, e254–e743.
2.
Lewis-Israeli, Y.R.; Wasserman, A.H.; Aguirre, A. Heart Organoids and Engineered Heart Tissues: Novel Tools for Modeling Human Cardiac Biology and Disease. Biomolecules 2021, 11, 1277.
3.
Liu, C.; Feng, X.; Li, G.; et al. Generating 3D human cardiac constructs from pluripotent stem cells. EBioMedicine 2022, 76, 103813.
4.
Peng, K.; Li, X.; Wu, C.; et al. Derivation of haploid trophoblast stem cells via conversion in vitro. iScience. 2019, 11, 508–518.
5.
Sharma, P.; Gentile, C. Cardiac spheroids as in vitro bioengineered heart tissues to study human heart pathophysiology. J. Vis. Exp. 2021, 167, e61962.
6.
Stiefbold, M.; Zhang, H.; Wan, L.Q. Engineered platforms for mimicking cardiac development and drug screening. Cell. Mol. Life Sci. 2024, 81, 197.
7.
Drakhlis, L.; Biswanath, S.; Farr, C.M.; et al. Human heart-forming organoids recapitulate early heart and foregut development. Nat. Biotechnol. 2021, 39, 737–746.
8.
Hofbauer, P.; Jahnel, S.M.; Papai, N.; et al. Cardioids reveal self-organizing principles of human cardiogenesis. Cell 2021, 184, 3299–3317.
9.
Rossi, G.; Broguiere, N.; Miyamoto, M.; et al. Capturing Cardiogenesis in Gastruloids. Cell Stem Cell 2021, 28, 230–240.
10.
Zimmermann, W.H.; Schneiderbanger, K.; Schubert, P.; et al. Tissue engineering of a differentiated cardiac muscle construct. Circ. Res. 2002, 90, 223–230.
11.
Mills, R.J.; Titmarsh, D.M.; Koenig, X.; et al. Functional screening in human cardiac organoids reveals a metabolic mechanism for cardiomyocyte cell cycle arrest. Proc. Natl. Acad. Sci. USA 2017, 114, E8372–E8381.
12.
Voges, H.K.; Mills, R.J.; Elliott, D.A.; et al. Development of a human cardiac organoid injury model reveals innate regenerative potential. Development 2017, 144, 1118–1127.
13.
Chen, Y.; Feng, J.; Zhao, S.; et al. Long-Term Engraftment Promotes Differentiation of Alveolar Epithelial Cells from Human Embryonic Stem Cell Derived Lung Organoids. Stem Cells Dev. 2018, 27, 1339–1349.
14.
Wang, X.; Yuan, Y.; Didelija, I.C.; et al. Ex Vivo Enteroids Recapitulate In Vivo Citrulline Production in Mice. J. Nutr. 2018, 148, 1415–1420.
15.
Lai Benjamin, F.L.; Lu RickX.; Hu, Y.; et al. Recapitulating pancreatic tumor microenvironment through synergistic use of patient organoids and organ-on-a-chip vasculature. Adv. Funct. Mater. 2020, 30, 2000545.
16.
Gomez-Mariano, G.; Matamala, N.; Martinez, S.; et al. Liver organoids reproduce alpha-1 antitrypsin deficiency-related liver disease. Hepatol. Int. 2020, 14, 127–137.
17.
Gleave, A.M.; Ci, X.; Lin, D.; et al. A synopsis of prostate organoid methodologies, applications, and limitations. Prostate 2020, 80, 518–526.
18.
Nowogrodzki, A. How cerebral organoids are guiding brain-cancer research and therapies. Nature 2018, 561, S48–S49.
19.
Maru, Y.; Tanaka, N.; Itami, M.; et al. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors. Gynecol. Oncol. 2019, 154, 189–198.
20.
Corro, C.; Novellasdemunt, L.; Li, V.S.W. A brief history of organoids. Am. J. Physiol. Cell Physiol. 2020, 319, C151–C165.
21.
Schmidt, C.; Deyett, A.; Ilmer, T.; et al. Multi-chamber cardioids unravel human heart development and cardiac defects. Cell 2023, 186, 5587–5605.
22.
Paik, D.T.; Cho, S.; Tian, L.; et al. Single-cell RNA sequencing in cardiovascular development, disease and medicine. Nat. Rev. Cardiol. 2020, 17, 457–473.
23.
Paik, D.T.; Chandy, M.; Wu, J.C. Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics. Pharmacol. Rev. 2020, 72, 320–342.
24.
Tang, Y.; Nyengaard, J.R.; Andersen, J.B.; et al. The application of stereological methods for estimating structural parameters in the human heart. Anat. Rec. 2009, 292, 1630–1647.
25.
Bergmann, O.; Zdunek, S.; Felker, A.; et al. Dynamics of Cell Generation and Turnover in the Human Heart. Cell 2015, 161, 1566–1575.
26.
Pinto, A.R.; Ilinykh, A.; Ivey, M.J.; et al. Revisiting Cardiac Cellular Composition. Circ. Res. 2016, 118, 400–409.
27.
Seguret, M.; Vermersch, E.; Jouve, C.; et al. Cardiac Organoids to Model and Heal Heart Failure and Cardiomyopathies. Biomedicines 2021, 9, 563.
28.
Schwach, V.; Passier, R. Native cardiac environment and its impact on engineering cardiac tissue. Biomater. Sci. 2019, 7, 3566–3580.
29.
Rossi, G.; Manfrin, A.; Lutolf, M.P. Progress and potential in organoid research. Nat. Rev. Genet. 2018, 19, 671–687.
30.
Cashman, T.J.; Josowitz, R.; Johnson, B.V.; et al. Human Engineered Cardiac Tissues Created Using Induced Pluripotent Stem Cells Reveal Functional Characteristics of BRAF-Mediated Hypertrophic Cardiomyopathy. PLoS ONE 2016, 11, e0146697.
31.
Hofbauer, P.; Jahnel, S.M.; Mendjan, S. In vitro models of the human heart. Development 2021, 148, dev199672.
32.
Silva, A.C.; Matthys, O.B.; Joy, D.A.; et al. Co-emergence of cardiac and gut tissues promotes cardiomyocyte maturation within human iPSC-derived organoids. Cell Stem Cell 2021, 28, 2137–2152.
33.
Little, M.H.; Combes, A.N. Kidney organoids: Accurate models or fortunate accidents. Genes Dev. 2019, 33, 1319–1345.
34.
Ming, Y.; Hao, S.; Wang, F.; et al. Longitudinal morphological and functional characterization of human heart organoids using optical coherence tomography. Biosens. Bioelectron. 2022, 207, 114136.
35.
Chen, G.; Ning, B.; Shi, T. Single-Cell RNA-Seq Technologies and Related Computational Data Analysis. Front. Genet. 2019, 10, 317.
36.
Asp, M.; Giacomello, S.; Larsson, L.; et al. A Spatiotemporal Organ-Wide Gene Expression and Cell Atlas of the Developing Human Heart. Cell. 2019, 179, 1647–1660.
37.
Gu, Y.; Gorelik, J.; Spohr, H.A.; et al. High-resolution scanning patch-clamp: New insights into cell function. FASEB J. 2002, 16, 748–750.
38.
Yamamoto, Y.; Hirose, S.; Wuriyanghai, Y.; et al. Electrophysiological Analysis of hiPSC-Derived Cardiomyocytes Using a Patch-Clamp Technique. Methods Mol. Biol. 2021, 2320, 1211–1233.
39.
Navarrete, E.G.; Liang, P.; Lan, F.; et al. Screening drug-induced arrhythmia using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation 2013, 128, S3–S13.
40.
66.Muller, J.; Ballini, M.; Livi, P.; et al. High-resolution CMOS MEA platform to study neurons at subcellular, cellular, and network levels. Lab. Chip. 2015, 15, 2767–2780.
41.
Eisner, D.A.; Caldwell, J.L.; Kistamas, K.; et al. Calcium and Excitation-Contraction Coupling in the Heart. Circ. Res. 2017, 121, 181–195.
42.
Zhang, J.Z.; Zhao, S.R.; Tu, C.; et al. Protocol to measure contraction, calcium, and action potential in human-induced pluripotent stem cell-derived cardiomyocytes. STAR Protoc. 2021, 2, 100859.
43.
Lee, J.; Sutani, A.; Kaneko, R.; et al. In vitro generation of functional murine heart organoids via FGF4 and extracellular matrix. Nat. Commun. 2020, 11, 4283.
44.
Horikoshi, Y.; Yan, Y.; Terashvili, M.; et al. Fatty Acid-Treated Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes Exhibit Adult Cardiomyocyte-Like Energy Metabolism Phenotypes. Cells 2019, 8, 1095.
45.
Dorn G.W., 2nd. Mitochondrial dynamism and heart disease: Changing shape and shaping change. EMBO Mol. Med. 2015, 7, 865–877.
46.
Kim, H.; Kamm, R.D.; Vunjak-Novakovic, G.; et al. Progress in multicellular human cardiac organoids for clinical applications. Cell Stem Cell. 2022, 29, 503–514.
47.
Schermelleh, L.; Heintzmann, R.; Leonhardt, H. A guide to super-resolution fluorescence microscopy. J. Cell Biol. 2010, 190, 165.
48.
Smith, C.L. Basic confocal microscopy. In Basic Confocal Microscopy; Springer: New York, NY, USA, 2001; Chapter 2, Unit 2.2.
49.
Richards, D.J.; Li, Y.; Kerr, C.M.; et al. Human cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity. Nat. Biomed. Eng. 2020, 4, 446–462.
50.
Ueda, H.R.; Erturk, A.; Chung, K.; et al. Tissue clearing and its applications in neuroscience. Nat. Rev. Neurosci. 2020, 21, 61–79.
51.
Huebsch, N.; Loskill, P.; Mandegar, M.A.; et al. Automated Video-Based Analysis of Contractility and Calcium Flux in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Cultured over Different Spatial Scales. Tissue Eng. Part C Methods 2015, 21, 467–479.
52.
Hayes, H.B.; Nicolini, A.M.; Arrowood, C.A.; et al. Novel method for action potential measurements from intact cardiac monolayers with multiwell microelectrode array technology. Sci. Rep. 2019, 9, 11893.
53.
Gao, J.; Liao, C.; Liu, S.; et al. Nanotechnology: New opportunities for the development of patch-clamps. J. Nanobiotechnology. 2021, 19, 97.
54.
Passaro, A.P.; Stice, S.L. Electrophysiological Analysis of Brain Organoids: Current Approaches and Advancements. Front. Neurosci. 2020, 14, 622137.
55.
Le Floch, P.; Li, Q.; Lin, Z.; et al. Stretchable Mesh Nanoelectronics for 3D Single-Cell Chronic Electrophysiology from Developing Brain Organoids. Adv. Mater. 2022, 34, e2106829.
56.
Li, Q.; Nan, K.; Le Floch, P.; et al. Cyborg Organoids: Implantation of Nanoelectronics via Organogenesis for Tissue-Wide Electrophysiology. Nano Lett. 2019, 19, 5781–5789.
57.
Shroff, S.N.; Das, S.L.; Tseng, H.A.; et al. Voltage Imaging of Cardiac Cells and Tissue Using the Genetically Encoded Voltage Sensor Archon1. iScience 2020, 23, 100974.
58.
Hou, J.H.; Kralj, J.M.; Douglass, A.D.; et al. Simultaneous mapping of membrane voltage and calcium in zebrafish heart in vivo reveals chamber-specific developmental transitions in ionic currents. Front. Physiol. 2014, 5, 344.
59.
Gaspar, J.A.; Doss, M.X.; Hengstler, J.G.; et al. Unique metabolic features of stem cells, cardiomyocytes, and their progenitors. Circ. Res. 2014, 114, 1346–1360.
60.
Lewis-Israeli, Y.R.; Wasserman, A.H.; Gabalski, M.A.; et al. Self-assembling human heart organoids for the modeling of cardiac development and congenital heart disease. Nat. Commun. 2021, 12, 5142.
61.
Ferrick, D.A.; Neilson, A.; Beeson, C. Advances in measuring cellular bioenergetics using extracellular flux. Drug Discov. Today 2008, 13, 268–274.
62.
Little, A.C.; Kovalenko, I.; Goo, L.E.; et al. High-content fluorescence imaging with the metabolic flux assay reveals insights into mitochondrial properties and functions. Commun. Biol. 2020, 3, 271.
63.
Ho, B.X.; Pang, J.K.S.; Chen, Y.; et al. Robust generation of human-chambered cardiac organoids from pluripotent stem cells for improved modelling of cardiovascular diseases. Stem Cell Res. Ther. 2022, 13, 529.
64.
Matkovich, S.J. Multiomic approaches to delineate the pathogenesis of cardiac disease. Curr. Opin. Cardiol. 2019, 34, 246–253.
65.
Mantri, M.; Scuderi, G.J.; Abedini-Nassab, R.; et al. Spatiotemporal single-cell RNA sequencing of developing chicken hearts identifies interplay between cellular differentiation and morphogenesis. Nat. Commun. 2021, 12, 1771.
66.
Bowes, J.; Brown, A.J.; Hamon, J.; et al. Reducing safety-related drug attrition: The use of in vitro pharmacological profiling. Nat. Rev. Drug Discov. 2012, 11, 909–922.
67.
Abilez, O.J.; Tzatzalos, E.; Yang, H.; et al. Passive Stretch Induces Structural and Functional Maturation of Engineered Heart Muscle as Predicted by Computational Modeling. Stem Cells 2018, 36, 265–277.
68.
Cho, S.; Lee, C.; Skylar-Scott, M.A.; et al. Reconstructing the heart using iPSCs: Engineering strategies and applications. J. Mol. Cell. Cardiol. 2021, 157, 56–65.
69.
Mannhardt, I.; Saleem, U.; Benzin, A.; et al. Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening. J. Vis. Exp. 2017, 122, e55461.
70.
Mills, R.J.; Parker, B.L.; Quaife-Ryan, G.A.; et al. Drug Screening in Human PSC-Cardiac Organoids Identifies Pro-proliferative Compounds Acting via the Mevalonate Pathway. Cell Stem Cell 2019, 24, 895–907.
71.
Tian, Y.; Tsujisaka, Y.; Li, V.Y.; et al. Immunosuppressants Tacrolimus and Sirolimus revert the cardiac antifibrotic properties of p38-MAPK inhibition in 3D-multicellular human iPSC-heart organoids. Front. Cell Dev. Biol. 2022, 10, 1001453.
72.
Zhu, L.; Liu, K.; Feng, Q.; et al. Cardiac Organoids: A 3D Technology for Modeling Heart Development and Disease. Stem Cell Rev. Rep. 2022, 18, 2593–2605.
Issue
Volume 3, Issue 3How to Cite
Liu, Y., Abraham, S., & Xu, H. (2024). Human Cardiac Organoids: Quantification and Qualification in Cardiovascular Studies. International Journal of Drug Discovery and Pharmacology, 3(3), 100017. https://doi.org/10.53941/ijddp.2024.100017
RIS
BibTex
Copyright & License
Copyright (c) 2024 by the authors.
This work is licensed under a This work is licensed under a Creative Commons Attribution 4.0 International License.